Edition:
United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

9.44USD
18 Apr 2019
Change (% chg)

$-0.40 (-4.07%)
Prev Close
$9.84
Open
$9.84
Day's High
$9.88
Day's Low
$9.30
Volume
104,292
Avg. Vol
70,528
52-wk High
$20.97
52-wk Low
$9.30

Cassella,, James 

Dr. James V. Cassella, Ph.D., is the Chief Development Officer of Concert Pharmaceuticals Inc, since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in physiological psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.

Basic Compensation

Total Annual Compensation, USD 406,445
Restricted Stock Award, USD 832,200
Long-Term Incentive Plans, USD --
All Other, USD 721,591
Fiscal Year Total, USD 1,960,240

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

167,720

Roger Tung

3,430,850

Marc Becker

--

Nancy Stuart

1,947,300

Lynette Herscha

--

James Cassella,

1,960,240
As Of  31 Dec 2017